Introduction {#Sec1}
============

Endothelin-1 (ET-1) is an endogenous vasoactive peptide. It is derived from endothelial cells and is also produced by other cell types, including inflammatory cells, tumor cells, and neurons \[[@CR1]--[@CR4]\]. ET-1 exerts its biological effects by binding to two specific G-protein-coupled receptors, endothelin-A receptor (ET~A~R) and endothelin-B receptor (ET~B~R) \[[@CR5], [@CR6]\]. In the peripheral nervous system, ET~A~R is expressed in nociceptive primary sensory neurons, including the dorsal root ganglion (DRG) neurons, whereas ET~B~R is mainly found in satellite glial cells \[[@CR7]\]. Numerous studies have demonstrated that ET-1 plays an important role in peripheral pain signaling. In humans, exogenous ET-1 causes tactile allodynia and severe pain \[[@CR8]\]. In rodents, an intraplantar injection of ET-1 produces mechanical and thermal hyperalgesia and spontaneous pain-like behaviors \[[@CR9]--[@CR12]\]. Paw withdrawal thresholds to mechanical stimuli and heat are significantly lower in conditional ET-1 knockout mice \[[@CR13]\]. Peripheral ET-1 acts on nociceptors through its cognate receptors, which subsequently modify pain-related ion channels to amplify signal generation \[[@CR14]\]. In DRG neurons, ET-1 increases neuronal excitation by hyperpolarizing tetrodotoxin-resistant (TTX-R) Na^+^ channels and suppressing the delayed outward rectifier current (*I*~K~) via ET~A~R \[[@CR15], [@CR16]\]. In contrast, ET-1 decreases the excitability of DRG neurons through the activation of ET~B~R \[[@CR17]\]. ET-1 potentiates TRPV1-mediated currents by an ET~A~R-mediated and protein kinase C (PKC)-dependent mechanism in both the expression system and sensory neurons \[[@CR18], [@CR19]\]. ET-1-induced pain-like behavior is attenuated in TRPV1-deficient mice \[[@CR20]\]. TRPV1 also contributes to ET-1-induced thermal and mechanical hyperalgesia \[[@CR10], [@CR21]\]. ET-1 sensitizes TRPA1 in primary sensory neurons via an ET~A~R and protein kinase A (PKA) pathway \[[@CR22]\]. TRPA1 is involved in ET-1-induced mechanical hyperalgesia and spontaneous pain-like behavior \[[@CR22], [@CR23]\]. However, ET-1-induced nociceptive responses are not completely inhibited in TRPV1-deficient mice or by TRPV1 and TRPA1 antagonists, suggesting that other mechanisms are also involved.

Acid-sensing ion channels (ASICs), such as pH sensors, are also pain-related ion channels. ASICs are expressed in both DRG cell bodies and sensory terminals, where they contribute to proton-evoked pain signaling \[[@CR24], [@CR25]\]. ASICs, rather than TRPV1, are shown to mainly mediate pain sensation induced by a moderate (up to pH 6.0) peripheral pH \[[@CR26]--[@CR29]\]. ASICs were found to be the major player in pain associated with tissue acidosis, such as inflammation, tissue damage, ischemia, and tumors \[[@CR30]--[@CR32]\]. Thus, ASICs represent a novel therapeutic target for pain \[[@CR32]--[@CR34]\].

ET-1 and protons activate their cognate receptors expressed in nociceptors and separately contribute to the nociceptive process. Since both endothelin receptors and ASICs are distributed in DRG neurons, we hypothesized that there may be an interaction between endothelin receptors and ASICs in the same DRG neuron. Herein, we showed that ET-1 enhanced the electrophysiological activity of ASICs in DRG neurons through ET~A~R, which may contribute to ET-1-induced spontaneous flinching and mechanical hyperalgesia in rats.

Materials and methods {#Sec2}
=====================

Isolation of DRG neurons {#Sec3}
------------------------

All experimental protocols were approved by the animal research ethics committee of Hubei University of Science and Technology. All procedures were performed to minimize the suffering of animals. Male Sprague-Dawley rats (5- to 6-week-old) were sacrificed. The DRGs were removed and minced with fine spring scissors. The ganglion fragments were placed in a flask containing 5 mL of Dulbecco\'s modified Eagle\'s medium (DMEM, Sigma). DMEM contained trypsin (type II-S, Sigma) 0.5 mg/mL, collagenase (type I-A, Sigma) 1.0 mg/mL and DNase (type IV, Sigma) 0.1 mg/mL, and were incubated at 35 °C in a shaking water bath for 25--30 min. Soybean trypsin inhibitor (type II-S, Sigma) 1.25 mg/mL was then added to stop trypsin digestion.

Electrophysiological recordings {#Sec4}
-------------------------------

Electrophysiological experiments were carried out as described previously \[[@CR35]\]. Whole-cell patch clamp and voltage-clamp recordings were carried out at room temperature (22--25 °C) using a MultiClamp-700B amplifier and Digidata-1440A A/D converter (Axon Instruments, CA, USA). Dissociated neurons were placed into a 35-mm Petri dish and were bathed in an external solution containing (mM): NaCl 150, KCl 5, CaCl~2~ 2.5, MgCl~2~ 2, HEPES 10, and *[d]{.smallcaps}*-glucose 10, and the pH and osmolarity were adjusted to 7.4 with NaOH and to 330 mOsm/L with sucrose, respectively. Cells were kept for at least 60 min in normal external solution before the start of electrophysiological experiments. The neurons selected for electrophysiological experiments were 15--35 μm in diameter, which are thought to be nociceptive neurons. Recording pipettes were pulled using a Sutter P-97 puller (Sutter Instruments, CA, USA). The micropipettes were filled with internal solution containing (mM): KCl 140, MgCl~2~ 2.5, HEPES 10, EGTA 11 and ATP 5; the pH of the solution was adjusted to 7.2 with KOH and its osmolarity was adjusted to 310 mOsm/L with sucrose. The resistance of the recording pipette was in the range of 3--6 MΩ. To establish a whole-cell configuration, a small patch of membrane underneath the tip of the pipette was aspirated to form a giga seal, and then, negative pressure was applied to rupture it. The series resistance was compensated for by 70%--80%. The capacitance compensation was also adjusted before recording the membrane currents. The membrane voltage was maintained at −60 mV in all voltage-clamp experiments. Current-clamp recordings were obtained by switching to current-clamp mode after a stable whole-cell configuration was formed in voltage-clamp mode. Only cells with a stable resting membrane potential (more negative than −50 mV) were used in the study. Signals were sampled at 10 to 50 kHz and filtered at 2 to 10 kHz, and the data were stored in a compatible PC computer for offline analysis using pCLAMP 10 acquisition software (Axon Instruments, CA, USA).

Drug application {#Sec5}
----------------

Drugs were obtained from Sigma Chemical Co. (St. Louis, MO, USA), including hydrochloric acid, ET-1, BQ-123, BQ-778, amiloride, APETx2, capsaicin, and AMG9810. Different pH values were configured with hydrochloric acid and external solution. Working ET-1 and other drugs were freshly prepared in normal external solution and held in a series of independent reservoirs. The pipette tips connecting the reservoirs were positioned ∼30 μm away from the recorded neurons. The application of each drug was driven by gravity and controlled by the corresponding valve. In some experiments where GDP-β-S (Sigma) or GF109203X (RBI) was applied for intracellular dialysis through recording patch pipettes, they were dissolved in the internal solution before use. To ensure that the cell interior was perfused with the dialysis drug, there was at least a 30 min interval between the establishment of whole-cell access and current measurement. To functionally characterize ASIC activity, we used AMG9810 (5 μM) to block TRPV1 in the extracellular solution \[[@CR36]\].

Cell culture and transfection {#Sec6}
-----------------------------

ASIC3 and ET~A~R complementary DNA (cDNAs) were used for heterologous expression in CHO cells as described previously \[[@CR37]\]. In brief, CHO cells were cultured at 37 °C in a humidified atmosphere of 5% CO~2~ and 95% O~2~ and passaged twice a week. Transient transfection of CHO cells was performed using a HilyMax liposome transfection reagent (Dojindo Laboratories). CHO cells were maintained in F-12 nutrient mixture (added 1.176 g of NaHCO~3~/L medium) supplemented with 10% fetal bovine serum and 1% gluta-MAXTM-1 (100 ×; Invitrogen). When ASIC3 and ET~A~R cDNA was cotransfected, the ratio was maintained at 1:1. All plasmids contained, in addition to the desired ASIC3 cDNA, the coding sequence for enhanced green fluorescent protein to aid in the identification of transfected cells. Electrophysiological measurements were performed 24--48 h after transfection.

Animal behavioral assay {#Sec7}
-----------------------

Rats were placed in a 30 × 30 × 30 cm Plexiglas chamber and allowed to habituate for at least 30 min before nociceptive behavioral experiments. A double-blind experiment was carried out. To assess ET-1-induced flinching, 49 rats were divided randomly into seven groups, with seven rats in each group. Separate groups of rats were coded and administered drugs. ET-1 (10 ng/paw) or vehicle (phosphate-buffered saline) was injected into the hind paw of rats using 100 μL syringe and 30-gauge needle in a volume of 50 μL, with BQ-123 (1 µg/paw), BQ-788 (100 ng/paw), amiloride (100 µM, 50 µL/paw) or APETx2 (10 μM, 50 µL/paw) co-injected with ET-1. The other experimenters measured nociceptive behavior. Flinching (time spent licking, biting, and lifting the injected paw) was counted for 50 min starting immediately after the injection. To assess ET-1-induced mechanical hyperalgesia, 42 rats were divided randomly into 6 groups, with seven rats in each group. Separate groups of rats were coded and administered drugs as above. Paw withdrawal thresholds (PWTs) were determined thereafter, at 0, 0.5, and 2.5 h after the injection. Paw withdrawal thresholds (PWTs) were tested using the up and down method \[[@CR38]\]. A series of von Frey filaments (Stoelting, Wood Dale, IL) were used to vertically press against the injected hind paw until the filaments were bent for 6 s. Quick withdrawal, licking or paw flinching were counted as positive reactions. The test was carried out many times in each rat, and the interval between tests was at least 5 min. All rats were tested only in one behavioral experiment, either for flinching or mechanical hyperalgesia.

Data analysis {#Sec8}
-------------

The data were statistically compared using Student\'s *t*-test or analysis of variance (ANOVA), followed by Bonferroni's post hoc test. Statistical analysis of concentration--response data was performed using the nonlinear curve-fitting program ALLFIT. The data are expressed as the mean ± S.E.M.

Results {#Sec9}
=======

Potentiation of ASIC currents by ET-1 in rat DRG neurons {#Sec10}
--------------------------------------------------------

In the present study, AMG9810 (5 μM) was added to the external solution to block proton-induced TRPV1 activation \[[@CR36]\]. As shown in Fig. [1a](#Fig1){ref-type="fig"}, a perfusion of pH 6.0 external solution to DRG neurons for 5 s caused a rapid inward current (*I*~pH6.0~). This *I*~pH6.0~ could be completely blocked by both 10 μM amiloride, a broad-spectrum ASIC channel blocker, and 2 μM APETx2, an ASIC3 blocker. However, capsaicin (50 nM) failed to evoke any membrane currents in the presence of AMG9810. Thus, these proton-induced currents were considered to be pure ASIC currents after AMG9810 blocked proton-induced TRPV1 activation.Fig. 1Potentiation of proton-gated currents by ET-1 in rat DRG neurons.**a** Representative current traces were produced by the application of a pH 6.0 acidic solution for 5 s on a DRG neuron. The proton-gated current (*I*~pH6.0~) could be blocked by 10 μM amiloride, a broad-spectrum ASIC channel blocker. This current was also blocked by 2 μM APETx2, an ASIC3 blocker. The proton-gated currents were recorded in the presence of AMG9810 (5 μM) to block proton-induced TRPV1 activation. Under such conditions, capsaicin (50 nM) failed to evoke any membrane currents. The membrane potential was clamped at --60 mV. **b** The sequential current traces illustrate that the *I*~pH6.0~ amplitude was enhanced by different concentrations of ET-1 in a representative DRG neuron. ET-1 was preapplied to external solution for 2 min. **c** The graph shows ET-1 concentration-dependently increased the *I*~pH6.0~ with an EC~50~ of 7.42 ± 0.21 nM. Each point represents the mean ± S.E.M of 8--10 cells.

In some DRG neurons sensitive to acid stimuli (62.50%, 10/16), we observed that the pre-application of ET-1 for 2 min increased the peak amplitude of the ASIC currents. As shown in Fig. [1b, c](#Fig1){ref-type="fig"}, the *I*~pH6.0~ was enhanced by ET-1 pretreatment, and the potentiation of the *I*~pH6.0~ was dependent upon the concentration of ET-1. Fig. [1b](#Fig1){ref-type="fig"} shows that the peak amplitude of the *I*~pH6.0~ increased as the concentration of pretreated ET-1 increased from 1 to 100 nM in a representative DRG neuron. The potentiation of the *I*~pH6.0~ was reversible after the washout of ET-1. Fig. [1c](#Fig1){ref-type="fig"} shows the concentration--response curve for ET-1 with an EC~50~ (half-maximal effective concentration) value of 7.42 ± 0.21 nM. The results indicated that ET-1 increased ASIC currents in rat DRG neurons in a concentration-dependent manner.

We then investigated whether the ET-1 potentiation of ASIC currents was dependent upon pH values. ASIC currents were measured by applying a range of different low pH values in the absence and presence of ET-1 (30 nM). Fig. [2a](#Fig2){ref-type="fig"} shows that the peak amplitudes of *I*~pH7.0~, *I*~pH6.0~, and *I*~pH5.0~ increased after the pre-application of ET-1 for 2 min. Fig. [2b](#Fig2){ref-type="fig"} shows the effect of ET-1 (30 nM) on the concentration--response curve to protons. First, the pre-application of ET-1 shifted the concentration--response curve to protons upwards, as indicated by an increase of 61.11% ± 4.33% in the maximal current response to protons in the presence of ET-1. Second, neither the Hill coefficient nor slope of the curve was significantly changed by ET-1 (pH: *n* = 1.89 ± 0.37; ET-1 + pH: *n* = 1.86 ± 0.42; *P* \> 0.1, Bonferroni's post hoc test). Third, the pH~0.5~ (pH for half-maximal activation) values of both curves also showed no significant difference (pH: pH~0.5~ = 5.81 ± 0.11; ET-1 + pH: pH~0.5~ = 5.94 ± 0.16; *P* \> 0.1, Bonferroni's post hoc test). We therefore concluded that the potentiation of the ASIC current by ET-1 was not due to a change in the apparent affinity of protons for ASICs.Fig. 2Upwards shift in the concentration--response curve for protons by ET-1.**a** Sequential currents were evoked by different low pH values in the absence and presence of ET-1 (30 nM) pretreatment. **b** Proton concentration--response curves for ASIC activation in the absence (white circle) and presence (black circle) of extracellular 30 nM ET-1. The pre-application of ET-1 shifted the concentration--response curve for protons upwards. Each point represents the mean ± S.E.M. of 7--10 neurons. All peak current values were normalized to the peak current maximally activated by pH 5.0 applied alone in the absence of ET-1 (marked with an asterisk). The figure shows averaged data fitted with the Hill equation.

Involvement of ET~A~R and PKC signaling in the ET-1 potentiation of ASIC currents {#Sec11}
---------------------------------------------------------------------------------

To verify whether the ET-1 potentiation of ASIC currents was mediated by ET receptors, we observed the effects of the selective ET~A~R antagonist BQ-123 and the selective ET~B~R antagonist BQ-788 on the ET-1 enhancement of ASIC currents. As shown in Fig. [3a, b](#Fig3){ref-type="fig"}, the amplitude of the *I*~pH6.0~ increased 59.39 % ± 9.47% after ET-1 (30 nM) pretreatment alone. However, the amplitude of the *I*~pH6.0~ increased only 8.97% ± 4.13% when both BQ-123 (100 nM) and ET-1 (30 nM) were coapplied to DRG neurons (*P* \< 0.01, compared with ET-1 alone, Bonferroni's post hoc test, *n* = 8; Fig. [3a, b](#Fig3){ref-type="fig"}). In contrast, ET-1 (30 nM) caused an increase of 54.48% ± 6.19% on the *I*~pH6.0~ after BQ-788 (100 nM) was coapplied with ET-1 (*P* \> 0.1, compared with ET-1 alone, Bonferroni's post hoc test, *n* = 8; Fig. [3a, b](#Fig3){ref-type="fig"}). These results indicated that ET~A~R, but not ET~B~R, is involved in the ET-1 potentiation of ASIC currents in rat DRG neurons.Fig. 3Receptor and intracellular signal transduction mechanisms underlying the potentiation of proton-gated currents by ET-1.The current traces in **a** and the bar graph in **b** show that the *I*~pH6.0~ was potentiated by ET-1 (30 nM) preapplied alone for 2 min, and the ET-1 potentiation of the *I*~pH6.0~ was blocked by the coapplication of the ET~A~R-specific antagonist BQ-123 (100 nM), but not by the ET~B~R-specific antagonist BQ-788 (100 nM). Statistical tests were performed using Bonferroni's post hoc test, and significance is shown as follows: \*\**P* \< 0.01, compared with control column, ^\#\#^*P* \< 0.01, compared with ET-1 alone column. *n* = 8 in each column. The current traces in **c** and the bar graph in **d** show the effects of ET-1 (30 nM) on the *I*~pH6.0~ with recording pipettes filled with normal internal solution, the nonhydrolyzable GDP analog GDP-β-S (500 μM), or the PKC inhibitor GF109203X (2 μM) containing internal solution. Intracellular dialysis of GDP-β-S or GF109203X almost completely abolished the potentiation of the *I*~pH6.0~ by ET-1. \*\**P* \< 0.01, post hoc Bonferroni's test, compared with normal internal solution. *n* = 8 in each column.

We further explored the signaling pathway downstream of ET~A~R in the ET-1 potentiation of ASIC currents using an intracellular dialysis technique. ET~A~R is most commonly associated with the G~q/11~ G-protein subtype, which activates PLC and leads to a cascade of events, including the activation of PKC \[[@CR5], [@CR39]\]. Thus, we internally applied GDP-β-S (a nonhydrolyzable GDP analog) or GF109203X (a selective PKC inhibitor) to DRG cells through recording patch pipettes. Unlike the increase of 59.39% ± 9.47% on the *I*~pH6.0~ produced under the normal internal solution condition, the pre-application of ET-1 (30 nM) for 2 min produced only increases of 6.54% ± 2.85% and 12.47% ± 3.06% on the *I*~pH6.0~ when GDP-β-S (500 μM) or GF109203X (2 μM), respectively, was included in the pipette solution (*P* \< 0.01, compared with normal internal solution, post hoc Bonferroni's test, *n* = 8; Fig. [3c, d](#Fig3){ref-type="fig"}). These results indicated that the potentiation of ASIC currents by ET-1 was dependent upon G-protein and PKC signaling.

To further verify whether ET-1 could enhance acid-evoked currents mediated by ASIC3, ASIC3 was coexpressed with ET~A~R in CHO cells. We observed that a rapid reduction in the extracellular pH from 7.4 to 6.0 for 5 s also caused a rapid inward current. The acid-evoked currents were ASIC3 currents, since they were blocked by 2 μM APETx2, an ASIC3 blocker. Similar to that observed in DRG neurons, the ASIC3 currents were enhanced by the pre-application of ET-1 (30 nM) in CHO cells co-expressing ASIC3 and ET~A~R (Fig. [4a, b](#Fig4){ref-type="fig"}). The ET-1 potentiation of ASIC3 currents was also inhibited after pharmacological blockade of ET~A~R by BQ-123 (Fig. [4a, b](#Fig4){ref-type="fig"}). In contrast, ET-1 had no effect on ASIC3 currents at a concentration of 30 nM in CHO cells expressing ASIC3 alone, but not expressing ET~A~R (Fig. [4c, d](#Fig4){ref-type="fig"}).Fig. 4Potentiation of proton-gated currents by ET-1 in CHO cells co-expressing ASIC3 and ET~A~R.The current traces in **a** and bar graphs in **b** show that the *I*~pH6.0~ was enhanced by ET-1 (30 nM) preapplied alone for 2 min in CHO cells co-expressing ASIC3 and ET~A~R. This enhancing effect was inhibited by the coapplication of ET-1 and BQ-123 (100 nM), but not by the coapplication of ET-1 and BQ-788 (100 nM). Statistical tests were performed using Bonferroni's post hoc test, and significance is shown as follows: \*\**P* \< 0.01. *n* = 6 in each column. The current traces in **c** and bar graphs in **d** show that ET-1 had no effect on the *I*~pH6.0~ in CHO cells expressing ASIC3 alone, but not expressing ET~A~R. Currents were normalized to the control (100%, white column). *n* = 5 in each column. The proton-gated current in CHO cells could be blocked by 2 μM APETx2, an ASIC3 inhibitor.

Enhancement of proton-evoked action potentials by ET-1 in rat DRG neurons {#Sec12}
-------------------------------------------------------------------------

Under current-clamp conditions, a stimulus of pH 6.0 could trigger bursts of action potentials (APs) in DRG neurons in the presence of 5 μM AMG9810 to block proton-induced TRPV1 activation (Fig. [5a](#Fig5){ref-type="fig"}). Similar to that observed under voltage-clamp conditions, ET-1 also increased the number of APs evoked by acidic stimuli in DRG neurons (Fig. [5a, b](#Fig5){ref-type="fig"}). As shown in Fig. [5b](#Fig5){ref-type="fig"}, the number of APs evoked by a stimuli of pH 6.0 increased in seven DRG neurons with ET-1 (30 nM) pretreatment for 2 min (*P* \< 0.01, paired *t*-test, *n* = 7, Fig. [5b](#Fig5){ref-type="fig"}). However, pretreatment with vehicle had no effect on the number of APs evoked by stimuli of pH 6.0 (*P* \> 0. 1, paired *t*-test; *n* = 7, Fig. [5c](#Fig5){ref-type="fig"}). These results indicated that ET-1 exerted an enhancing effect on acid-evoked action potentials in rat DRG neurons.Fig. 5Enhancement of acid-evoked action potentials by ET-1 in rat DRG neurons.**a** Under current-clamp conditions, action potentials were evoked by a pH 6.0 acid stimulus in two DRG neurons with ET-1 (30 nM) or vehicle pretreatment for 2 min. AMG9810 (5 μM) was used to block proton-induced TRPV1 activation. **b**, **c** The graphs show the pre-application of ET-1 (30 nM), but not vehicle, increased the number of action potentials by pH 6.0 acid perfusions. \*\**P* \< 0.01, paired *t*-test, *n* = 7 cells.

Attenuation of ET-1-induced flinching and mechanical hyperalgesia by the pharmacological blockade of ET~A~R, ET~B~R, or ASICs in rats {#Sec13}
-------------------------------------------------------------------------------------------------------------------------------------

We finally examined the contribution of ASICs to ET-1-induced nocifensive behavior in vivo. Rats displayed an obvious flinching response after ET-1 (10 ng/paw) was injected subcutaneously into the ipsilateral hind paw compared with rats receiving vehicle injection only (Fig. [6a](#Fig6){ref-type="fig"}). The ET-1-induced flinching was almost completely blocked by subcutaneous cotreatment with BQ-123 (100 ng/paw), but not with BQ-788 (100 ng/paw). As shown in Fig. [6a](#Fig6){ref-type="fig"}, when ASICs blocker amiloride (100 µM, 50 µL/paw) or ASIC3 blocker rAPETx2 (10 μM, 50 µL/paw) was coadministered subcutaneously with ET-1 (10 ng/paw), it significantly attenuated hind paw flinching (*P* \< 0.05, Bonferroni's post hoc test, compared with ET-1 alone group, *n* = 7 rats). Rats injected with ET-1 into the hind paw (10 ng/paw) also displayed obvious mechanical hyperalgesia, measured 0.5 and 2.5 h after injection (Fig. [6b, c](#Fig6){ref-type="fig"}). ET-1-induced mechanical hyperalgesia disappeared 24 h after injection. Fig. [6b](#Fig6){ref-type="fig"} shows that ET-1-induced mechanical hyperalgesia was partially attenuated by subcutaneous cotreatment with BQ-123 (100 ng/paw) or BQ-788 (100 ng/paw). Furthermore, the intraplantar application of both BQ-123 (100 ng/paw) and BQ-788 (100 ng/paw) together almost completely blocked the mechanical hyperalgesia induced by ET-1 (Fig. [6b](#Fig6){ref-type="fig"}). As shown in Fig. [6c](#Fig6){ref-type="fig"}, amiloride (100 µM, 50 µL/paw) or APETx2 (10 μM, 50 µL/paw) also significantly attenuated the mechanical hyperalgesia induced by ET-1 (*P* \< 0.05 and 0.01, Bonferroni's post hoc test, compared with ET-1 alone group, *n* = 7 rats). The injection of these antagonists alone at the same dosage used above did not produce any effects on the number of flinches or the PWT (data not shown). Together, these results demonstrated that ASICs mediated, at least partially, ET-1-induced flinching and mechanical hyperalgesia.Fig. 6Attenuation of ET-1-induced flinching and mechanical hyperalgesia by the pharmacological blockade of ET~A~R, ET~B~R, or ASICs in rats.**a** ET-1-induced flinching was prevented by the ET~A~R-specific antagonist BQ-123, but not by the ET~B~R-specific antagonist BQ-788. When the ASIC blocker amiloride or APETx2 was subcutaneously administered together with ET-1, ET-1 induced an attenuated flinching response. **b** ET-1-induced mechanical hyperalgesia was attenuated by BQ-123 or BQ-788 alone and was blocked by the combined application of BQ-123 and BQ-788. **c** ET-1-induced mechanical hyperalgesia was also attenuated after the pharmacological blockade of ASICs by amiloride or APETx2. Flinching and mechanical hyperalgesia were induced by the injection of ET-1 subcutaneously into the rat plantar hind paw. Spontaneous flinching was evaluated by the time spent licking/lifting the injected paw (in seconds). The paw withdrawal threshold (PWT, in g) of rats was measured by von Frey hair test before injection (0 h) and 0.5, 2.5, 24 h after injection. BQ-123 (100 ng/paw) and/or BQ-788 (100 ng/paw), amiloride (100 µM, 50 µL/paw), or APETx2 (10 μM, 50 µL/paw) were co-injected with ET-1 (10 ng/paw) into the hind paw of rats. *n* = 7 rats in each group. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, Bonferroni's post hoc test, compared with the ET-1 alone group.

Discussion {#Sec14}
==========

We demonstrated here that ET-1 sensitized ASICs through ET~A~R. ET-1 increased ASIC-medicated currents and action potentials in rat primary sensory neurons, which may contribute to ET-1-induced spontaneous flinching and mechanical hyperalgesia in rats.

Low pH-evoked currents are mediated by proton-gated ion channels, including ASICs and TRPV1 \[[@CR40]\]. In the present study, the activation of TRPV1 channels was completely blocked by AMG9810, so capsaicin failed to evoke any membrane currents. We believe that ASICs mediated these low pH-evoked currents, which could be completely blocked by ASIC channel blockers; these evoked currents were, therefore, considered to be ASIC currents, although precise ASIC subunits need to be identified. To date, at least seven ASIC subunits have been identified in mammals. There are six ASIC subunits (ASIC1a and b, ASIC2a and b, ASIC3, and ASIC4) expressed in both DRG cell bodies and sensory terminals \[[@CR24], [@CR25]\]. These ASIC subunits exist as homomeric or heteromeric channels in DRG neurons. The ASIC3 subunit is the most abundant in DRG and has emerged as a critical pH sensor \[[@CR26], [@CR32]\].

The current data demonstrated that ET-1 can enhance the electrophysiological activity of ASICs in rat DRG neurons. ET-1 increased not only ASIC-mediated currents in voltage-clamp experiments but also the number of action potentials evoked by extracellular acid stimuli in current-clamp experiments. Obviously, the two results corroborated each other. ET-1 shifted the proton concentration--response curve upward without changing the pH~0.5~. Thus, the sensitization of ASICs by ET-1 did not change the apparent affinity of protons for ASICs.

We found that ET-1 sensitized ASICs in rat DRG neurons through ET~A~R, but not through ET~B~R, because the ET-1 potentiation of ASIC currents was completely blocked by the selective ET~A~R antagonist BQ-123 and was not affected by the selective ET~B~R antagonist BQ-788. In CHO cells co-expressing ASIC3 and ET~A~R, ET-1 also sensitized ASIC3 through ET~A~R. Together, ET~A~R, but not ET~B~R, appeared to contribute to the ET-1 potentiation of ASIC currents. The results were consistent with the expression characteristics of ET~A~R and ET~B~R in primary sensory neurons. ET~A~R is present in a subset of small- and medium-sized DRG neurons and their axons, whereas ET~B~R is mainly expressed by satellite glial cells and nonmyelinating Schwann cells, but not neurons \[[@CR7]\]. It has been found that ET~A~R is mainly expressed in isolectin B4-negative (IB4^−^) DRG neurons \[[@CR41]\]. ASICs are also more prevalent in IB4^−^ DRG neurons than in IB4^+^  neurons \[[@CR42]\]. Thus, the ET-1 potentiation of ASICs may mainly occur in peptidergic and IB4^-^ DRG neurons. ET~A~R belongs to a subfamily of GPCRs and is coupled to multiple second messenger systems. Although ET~A~R couples to G~s~ in other tissues, ET-1 does not increase intracellular cAMP levels in isolated DRG neurons \[[@CR43]\]. ET~A~R also couples to G~q/11~ to activate PLCβ, which, in turn, produces IP~3~ and DAG, followed by intracellular Ca^2+^ release and the activation of PKC \[[@CR5], [@CR39], [@CR44]\]. ET-1 can trigger intracellular calcium mobilization through ET~A~R in DRG neurons \[[@CR45]\]. ET~A~R, but not ET~B~R, activates PKC in peptidergic, IB4^−^ sensory neurons \[[@CR41]\]. In the present study, the lack of ET-1 potentiation in DRG neurons treated with GDP-β-S or the PKC inhibitor GF109203X indicated that a G-protein- and PKC-dependent pathway was involved in the sensitization of ASICs by ET-1. It has been shown that PKC is involved in the ET-1-mediated enhancement of capsaicin-induced Ca^2+^ increases in sensory neurons. ET-1 potentiates TRPV1 currents via the ET~A~R-mediated activation of PKC in both DRG neurons and the trigeminal ganglion neurons \[[@CR18], [@CR19]\]. The stimulation of ET~A~R by ET-1 inhibits inward rectifier K^+^  channels via the PKC pathway \[[@CR46]\]. However, ET-1 sensitizes TRPA1 via the ET~A~R and PKA pathways in primary sensory neurons \[[@CR22]\]. Our previous studies show that ASICs are modulated by intracellular PKC signaling \[[@CR35], [@CR37]\].

Initial studies show that exogenous ET-1 elicits spontaneous pain and hyperalgesia. In the present study, rats displayed flinching responses and mechanical hyperalgesia after ET-1 was injected subcutaneously into the ipsilateral hind paw. ET-1-induced flinching was almost completely blocked by subcutaneous cotreatment with BQ-123, but not BQ-788, suggesting this behavior is mediated by ET~A~R, but not ET~B~R. A combined intraplantar injection of BQ-123 and BQ-788 completely blocked ET-1-induced mechanical hyperalgesia, suggesting it is mediated by both ET~A~R and ET~B~R. Previous studies have shown that a subcutaneous injection of ET-1 into the rat plantar hind paw induces flinching behavior and spike responses in nociceptors through ET~A~R \[[@CR9], [@CR47]\]. It has been shown that ET~A~R activation contributes to ET-1-induced pain-like behavior and thermal hyperalgesia \[[@CR9], [@CR10], [@CR48]\]. In contrast, ET-1-induced mechanical hyperalgesia requires both ET~A~R and ET~B~R activation \[[@CR11], [@CR21], [@CR49]\]. ET-1 has been implicated in inflammation, so we cannot rule out ET-1-elicited nociceptive behavior that may be due to the induction of inflammatory responses after hind paw injection. However, some studies also show that ET-1 elicits nociceptive behavior due to ET-1's direct action on primary afferents, since this nociceptive behavior is mediated by ET~A~R located immunocytochemically on primary afferents \[[@CR7], [@CR9]\]. In this work, we used cell bodies of DRG neurons as a simple and accessible model to examine the characteristics of the membrane of peripheral terminals. The sensitization of ASICs by ET-1 may also occur in peripheral terminals. The pharmacological blockade of ASICs significantly alleviated ET-1-induced flinching and mechanical hyperalgesia in rats, suggesting that ASICs mediated, at least partially, ET-1-induced nociceptive behavior. It is possible that ET-1 sensitizes ASICs on primary afferents, which underlies ET-1-induced nociceptive behavior.

During tissue damage and inflammation, ET-1 is generated and released in a variety of cells, such as endothelial cells, monocytes and macrophages, which results in an increase of local ET-1 levels \[[@CR3], [@CR4]\]. DRG neurons are also an important source of ET-1 \[[@CR1]\]. ET-1 can excite these sensory neurons in a paracrine or autocrine manner. ET-1 levels are higher within a cancerous microenvironment, and the administration of an ET~A~R antagonist alleviates cancer pain \[[@CR3], [@CR5], [@CR50], [@CR51]\]. Thus, an endogenous concentration of ET-1 in diseased tissue is required to cause pain. The present tested concentration of ET-1 (30 nM) falls within the endogenous concentration of ET-1 ranges reported \[[@CR52]\]. ET-1 is implicated in the pathogenesis of a variety of types of pain, such as inflammatory, neuropathic, and tumoral pain \[[@CR5], [@CR14], [@CR53]\]. During tissue damage and inflammation, protons are released from damaged cells and the degranulation of mast cells. These released protons result in a drop in the local extracellular pH. For instance, the local extracellular pH drops to approximately 5.4 during acute inflammation, which is low enough to activate ASICs and cause pain \[[@CR30], [@CR54]\]. An acidic pH is commonly associated with cancerous microenvironments, contributing to cancer-related pain via the activation of ASICs and TRPV1 \[[@CR55], [@CR56]\]. Under inflammatory and cancer states, once both ET-1 and protons are locally released together in diseased tissue, and they activate their cognate receptors expressed in nociceptors to initiate and/or sensitize nociceptive processes. Furthermore, the present study showed that released ET-1 could sensitize ASICs through ET~A~R. ET-1 and protons may potentially work synergistically to produce more intense pain and mechanical hyperalgesia.

Conclusion {#Sec15}
==========

In summary, the major finding of this study was that ET-1 enhanced the electrophysiological activity of ASICs in DRG neurons via the intracellular PKC signaling pathway, which may contribute to ET-1-induced nociceptive behavior in rats. Our results demonstrated that ASICs act as novel targets of ET-1, which may provide a strategy for the treatment of pain associated with ET-1, such as inflammatory pain and cancer-related pain.
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